Team Overview

With the notion of science above everything else, a strong tumor research team has been formed, combined with the academic background and interests of the scientists, and concentrated on tackling key tumor science and clinical core issues.

Qimin Zhan

Senior Principal Investigator; SZBL Director


Research Areas

Long-term commitment to tumor molecular biology and tumor translational medicine research, focusing on the major basic issues of cell cycle and cell fate determination, focusing on spindle assembly protein machinery and cell division checkpoints, non-coding RNA, organelle communication and other directions. At the same time, he is committed to the research of gastrointestinal tumors, especially the molecular mechanism and diagnosis and treatment targets of the high incidence of esophageal squamous cell carcinoma in my country.


  • Academician, Chinese Academy of Engineering
  • Distinguished Professor, Changjiang Scholar Program, Ministry of Education, China
  • National Science Fund for Distinguished Young Scholars
  • National Award, New Century Talents Project
  • Chief Scientist, Innovation Committee, National Natural Science Foundation of China

Pictorial View

  • 1.png


  • 2019- Present
    Laboratory Director,Shenzhen Bay Laboratory
  • 2019 - Present
    Chancellor,Peking University Shenzhen Graduate School
  • 2017 - 2020
     Vice President/Executive Vice President,Peking University
  • 2016 - Present
    President,Health Science Center, PKU
  • 2005 - 2016
    Vice President,Chinese Academy of Medical Sciences
  • 2005 - 2016
    Vice President,Peking Union Medical College
  • 2002 - Present
    Director,State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences
  • 1998 - 2003
     Assistant Professor/Tenure Associate Professor,University of Pittsburgh School of Medicine 
  • 1989 - 1996
    Postdoc,University of California & University of Texas & NIH


Internationally, it is the first to discover and systematically clarify the biological function and regulation mechanism of cell cycle checkpoints, revealing from a deep level the mechanism of abnormal cell cycle regulation leading to cell carcinogenesis. The first report on the genomic mutation of esophageal cancer in the world, comprehensively and systematically reveals the important gene mutations, copy number changes and gene structure mutations in the occurrence and development of esophageal cancer, providing a rich theoretical basis for early tumor diagnosis, screening drug targets, and optimizing clinical treatment And experimental basis. He has published more than 240 SCI academic papers, SCI has cited more than 14,000 times, and edited 7 books.

Selected Publications

Song, Yongmei et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91-95.

Li, Dan et al. Long Noncoding RNA HULC Modulates the Phosphorylation of YB-1 Through Serving as a Scaffold of Extracellular Signal_x0002_Regulated Kinase and YB-1 to Enhance Hepatocarcinogenesis. Hepatology. 2017;65:1612-1627.

Wu, Qingnan et al. APC/C-CDH1-Regulated IDH3beta Coordinates with the Cell Cycle to Promote Cell Proliferation. Cancer Research. 2019;79:3281-93.

Yan, Ting et al. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nature Communications. 2019;10(1): 1670.

Li, Xianfeng et al. OncoBase: a platform for decoding regulatory somatic mutations in human cancers. Nucleic Acids Res. 2019;47:D1044-D1055.